Updated:
NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage biotech firm developing therapies for ALS and Alzheimer's.
NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. was incorporated as a clinical-stage biotechnology firm without a disclosed founding year or named founders in public records. The company's wealth origin is not publicly attributed to a single family or principal, operating instead as a publicly traded entity that also engages institutional and retail investors through capital markets (per public record). The firm's strategy centers on developing therapies for neurodegenerative disorders, with a pipeline that includes primeC, a novel combination drug for ALS that completed a Phase 2b trial, and other candidates for Alzheimer's disease and Parkinson's disease. NeuroSense funds its operations through equity offerings and partnerships, with a confirmed clinical-stage approach that targets shared pathological pathways such as RNA regulation and protein aggregation (per public filings). Geographic footprint is primarily Israel-based with operations extending to the US for regulatory and clinical activities. As of mid-2025, NeuroSense had not disclosed a total deployment figure or team size. The firm maintains no publicly listed additional offices beyond its stated headquarters. Adjacent structures include publicly traded shares on Nasdaq under the ticker NRSN, which provides a capital-formation vehicle distinct from a private family office. No philanthropic foundation or operating business arm was identified in public records. A key structural differentiator is NeuroSense's hybrid model as a publicly traded biotechnology firm that retains characteristics of a development-stage company, funding clinical trials through public markets rather than private capital alone. This structure gives it a distinct regulatory posture compared to privately held biotech firms, with disclosure obligations under SEC regulations (per public record).
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at NeuroSense Therapeutics?
Investment decisions at NeuroSense are directed by its board of directors and executive management team. As a publicly traded company, capital allocation—including R&D spending and fundraising—is overseen by the CEO and CFO, with strategic input from the board. Public filings with the SEC identify named officers, though specific investment professionals are not separately listed (per public record).
How does NeuroSense Therapeutics source proprietary deal flow?
NeuroSources its drug candidates internally through its scientific team's research into neurodegenerative disease biology, as well as through academic collaborations. The firm has licensed technology from institutions such as Tel Aviv University for its primeC formulation (per public disclosures). This internal R&D pipeline is the primary sourcing mechanism, distinct from a venture capital model.
Is NeuroSense Therapeutics structured as a single family office or does it operate more like a biotechnology firm?
NeuroSense is organized as a publicly traded biotechnology company, not a family office. It is listed on Nasdaq under the ticker NRSN and operates with the governance, disclosure, and capital-markets obligations of a public company. This structure provides liquidity to shareholders through secondary trading, unlike a private family office vehicle (per public record).
Does NeuroSense Therapeutics participate in fund commitments or only direct deals?
As a clinical-stage biotech firm, NeuroSense does not act as a fund manager or make fund commitments. Its capital deployment is entirely direct into its own drug development programs. The company raises capital through equity offerings and at-the-market programs rather than through partnerships with external GPs (per SEC filings).
What investment stages does NeuroSense Therapeutics typically target?
NeuroSense employs its capital in clinical-stage drug development, specifically targeting Phase 2 and Phase 3 trials for its lead candidate primeC in ALS. The firm also supports preclinical research for earlier-stage programs in Alzheimer's and other neurodegenerative diseases. This stage focus reflects a biotech R&D model rather than a traditional venture capital stage framework (per public disclosures).
Which sectors does NeuroSense Therapeutics explicitly avoid?
NeuroSense does not publicly disclose exclusionary sector policies. Given its therapeutic focus, the firm's entire portfolio is concentrated in neurodegenerative disease treatments, with no disclosed involvement in other asset classes or sectors such as technology, real estate, or hedge funds (per public record).
How is NeuroSense Therapeutics related to any parent or related vehicles?
NeuroSense Therapeutics Ltd. is a standalone publicly traded entity with no disclosed parent company or affiliated family office. It does not operate as a vehicle for a single family's wealth, and its major shareholders include institutional investors and individual shareholders as disclosed in SEC filings (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: